Emergent BioSolutions (EBS) reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.
Three analysts polled by FactSet, on average, expected a $0.43 loss.
Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.
Four analysts expected $249.5 million.
For Q1, the company is projecting $200 million to $240 million in revenue.
One analyst expects $279 million.
For 2025, the company is expecting $750 million to $850 million in revenue.
Three analysts are looking for $1.11 billion.
Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.